THE EFFECT OF VALERIAN ON THE PHARMACOKINETICS OF CARBAMAZEPINE IN HEALTHY RABBITS

Issam Abushammala

Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University-Gaza, P.O box: 1277, Palestine.

Keywords: Carbamazepine, Valerian, Pharmacokinetic, Interaction.

ABSTRACT: The aim of this article was to evaluate the effect of valerian on a single dose kinetic of carbamazepine in rabbits. Five healthy male rabbits in a randomized, two-crossover design were enrolled in this study. Rabbits were divided into two groups; the first received a single dose of 100 mg carbamazepine (CBZ) suspension. The second group received CBZ 100 mg suspension concurrently with valerian (VAL) 25 mg dry extract. After a washout period of one week the doses were given in a reverse manner. Blood samples were collected over a period of 24 hours. Serum was assayed for CBZ using chemiluminescent enzyme immunoassay (CLEIA). Pharmacokinetic (PK) parameters were determined for CBZ in both cases using non-compartmental analysis. Statistically insignificant differences $P \geq 0.05$ were found in PK parameters when CBZ was given alone or concurrently with VAL; the values were $C_{\text{max}}$ 6.52 ± 1.6 µg/ml versus 5.32 ± 1.4 µg/ml, $t_{\text{max}}$ 2.6 ± 0.9 h versus 3.3 ± 0.9 h, $\text{AUC}_{0-24}$ 83.80 ± 28.8 µg·h/ml versus 60.4 ± 12 µg·h/ml, $\text{AUC}_{0-\infty}$ 166.20 ± 74 µg·h/ml versus 104.75 ± 12 µg·h/ml, $k_e$ 0.033 ± 0.006 h$^{-1}$ versus 0.038 ± 0.012 h$^{-1}$ and $t_{1/2}$ 21.81 ± 3.96 h versus 20.71 ± 10.09 h respectively. The result of the study demonstrated that valerian does not affect PK of CBZ, there are no cautions, regarding to dose or administration pattern of CBZ with valerian should be taken.

INTRODUCTION: Carbamazepine (CBZ) is one of the commonly used conventional antiepileptic drugs. CBZ has a considerable low therapeutic index and a wide inter-individual variation at tolerable doses which make therapeutic drug monitoring necessary. In addition, CBZ is a potent enzyme inducer and is a subject to autoinduction. Those properties make CBZ prone to interactions with co-administered drug, herbal products and food. Drug interactions are classified into pharmacodynamic and pharmacokinetic types. The variability in drug pharmacokinetic is responsible for the lack of a consistent relationship between dose given of the drug and its concentration at the site of action.

Herb-drug interactions are mostly pharmacokinetic. Fluctuations in bioavailability of drug and herb molecules in the body can result from changes in absorption, distribution, metabolism and elimination. Induction or inhibition of hepatic and intestinal drug-metabolizing enzymes e.g. CYP450 and/or drug transporters such as P-glycoprotein were suggested as possible mechanisms. 

DOI: 10.13040/IJPSR.0975-8232.5(9).3641-45

Article can be accessed online on: www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.5(9).3641-45

Issam Abushammala, IJPSR, 2014; Vol. 5(9): 3641-3645

E-ISSN: 0975-8232; P-ISSN: 2320-5148

International Journal of Pharmaceutical Sciences and Research 3641
The consumption of herbal products for a variety of health-related problems has steadily increased over the past few years. Valerian (VAL) is a popular herbal product often used to treat insomnia and anxiety. It is the most common non-prescription sedative used in Europe. CBZ-herb interactions were an interesting and important issue for many researchers. Possible pharmacokinetic VAL-CBZ interactions are still uninvestigated. The present study aims to examine the effect of VAL on PK of CBZ in healthy rabbits.

MATERIALS AND METHODS:

Animals
Five healthy male rabbits (weight: 3.26 ± 0.11 Kg, age: 7-9 months) were enrolled in the study. The rabbits were obtained from Asdda for animal production and welfare centre, where follow up care and clinical examination were performed and rabbits’ health state was certified (khanunis, Palestine). Rabbits were fasted for 12 hours with free access to water by add libitum before begin of the study. The study was carried out at Al-Azhar University-Gaza, College of Pharmacy, Gaza, Palestine. The study was approved by the institutional ethic committee and was conducted under supervision of a veterinary physician.

Study design
A single dose, two-crossover design study was conducted in rabbits. The rabbits were divided into two groups. The first one received a volume equivalent to 100 mg CBZ from an oral suspension 2% (Tegretol, Novartis), whereas the second group received the same volume of CBZ suspension in combination with a volume of prepared in laboratory suspension equivalent to 25 mg valerian dry extract. It was prepared by pulverizing five tablets of commercial valerian film coated tablets (Relaxine, Laboratoires Pharmaceutiques Trenker). Each tablet contains 500 mg of valerian dry extract. A weight of the powder equivalent to 0.5 g VAL dry extract was suspended in 20 ml distilled water. After one week the second group received CBZ suspension alone and the first received CBZ suspension in combination with VAL to complete the cross-over design. Carbamazepine oral suspension and valerian tablets were purchased from a local pharmacy (Gaza, Palestine). The dose was given orally by gavage to each rabbit. It was put in the corner of the mouth and the suspension was pushed down slowly, to avoid choking. General clinical safety was assessed by physical examination during the study, washout period and at the end of the study.

Blood sampling
Rabbits were placed in rabbit restraining box device. The marginal ear vein was located and the hair was removed. Gentle stroking and tapping of the ear may make the vein more visible. Local anesthetic was applied to prevent the jerking of the rabbit as a result of venipuncture 15 minutes before starting the study. Inserting a small needle (23 gauge) butterfly attached to a syringe in the marginal ear vein. Serial venous blood samples were collected (ca. 0.7 ml) in vacutainer tubes according to the time schedule 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0 and 24.0 h after receiving the dose. Blood samples were centrifuged at 3,000 rpm for 5 minutes and serum was transferred into clean plastic tubes. Serum samples (ca. 200 µl) were kept in refrigerator until being analyzed within 24 h.

Analysis of serum samples
Analysis was performed by Carbamazepine kit based on chemiluminescent enzyme immunoassay (CLEIA) and Immulite 1000 immunoassay system (Siemens Healthcare Diagnostics).

Pharmacokinetic analysis
The plasma pharmacokinetic parameters were estimated, which included the observed maximum plasma concentration C_max, the time to reach C_max, (T_max) and the area under the plasma concentration-time curve from 0 hour to last measurable concentration (AUC_0-t) and 0 hour to infinity (AUC_0-∞). The C_max and T_max were directly determined from the serum concentration versus time curves. The Area under the curve from 0 hour to t (AUC_0-t) was calculated by the linear trapezoidal rule. The area under the curve from 0 hour to infinity (AUC_0-∞) was estimated by summing the area from AUC_0-t and AUC_0-∞, where AUC_0-∞ = AUC_0-t + C_t / k_e, with ‘C_t’ defined as the last measured serum concentration at time t, and k_e is the elimination rate constant. The elimination rate constant k_e was estimated by the least squares regression of plasma concentration-time data points lying in the terminal region by using semilogarithmic dependence that corresponds to first-order kinetics. The half-life t_1/2 was calculated as 0.693/k_e. Pharmacokinetic analysis was performed by means of model independent method (Non-Compartmental Approach) WinNonlin.

Statistical analysis
Analysis of Variance (ANOVA) was used to compare the calculated pharmacokinetic parameters of CBZ alone or with VAL, using general linear model procedures, in which sources of variation were subject and period. The statistical analysis was performed using SPSS, version 16. A statistically significant difference was considered when P ≤ 0.05.

RESULTS AND DISCUSSION:
Carbamazepine (CBZ) is a first-line antiepileptic drug which may be prone to drug interactions. Serious herb-carbamazepine interactions with clinical evidence were reported. The majority were pharmacokinetic based.

In this study the effect of VAL on PK of CBZ was investigated using rabbits. The mean plasma concentrations of CBZ when administered alone or in combination with VAL are shown in Fig 1.

The concentration time profile in both cases obviously indicated that they were comparable. The mean $C_{\text{max}}$ were $6.52 \pm 1.6$ µg/ml versus $5.32 \pm 1.4$ µg/ml, and $t_{\text{max}}$ were $2.6 \pm 0.9$ h versus $3.3 \pm 0.9$ h, of CBZ after alone and concomitant administration of CBZ with VAL, respectively. Table 1. VAL has not changed absorption phase of CBZ. Some herbal products increased absorption of poor water soluble CBZ - through enhancement of dissolution or altering gastric emptying rate. Psyllium, septilin and soya bean decreased bioavailability and plasma level of CBZ by affecting its gastric absorption.

By comparing the rest PK parameters, statistically insignificant differences were found. The elimination of CBZ was not affected by VAL; $K_e$ and $t_{1/2}$ were not changed when VAL was co-administered significantly. CYP3A4 is the most important enzyme involved in the metabolism of CBZ as it leads to the formation of the active metabolite CBZ 10,11-epoxide, which appears to contribute to the toxicity and efficacy of CBZ. CYP3A6 is responsible for CBZ metabolism in the rabbit. The rabbit CYP3A6 and human CYP3A4 isoform have similar p-450 predominance and substrate specificity and both are induced by rifampicin. CYP3A4 is the most important isoform of CYP450 in critical tissues, such as hepatic and gastrointestinal tract. This enzyme is involved in the biotransformation of over 70% of the drugs in use today; hence, the possible risk of adverse events due to alterations in this pathway is high. Some herbal products induced CYP3A4 and diminished CBZ plasma level e.g. Ginko biloba and soybean. Others like grapefruit juice and Polygonum cuspitatum inhibited CYP3A4 led to elevated plasma level of CBZ.

### TABLE 1: SUMMARY OF MEAN PHARMACOKINETIC PARAMETERS OF CBZ 100 MG WITH AND WITHOUT VAL 25 MG (n=5).

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter$^a$</th>
<th>CBZ alone Mean ± SD$^b$</th>
<th>CBZ and VAL Mean ± SD$^b$</th>
<th>p-Value$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (µg/ml)</td>
<td>6.52 ± 1.66</td>
<td>5.320 ± 1.386</td>
<td>0.355</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (h)</td>
<td>2.60 ± 0.96</td>
<td>3.300 ± 0.975</td>
<td>0.404</td>
</tr>
<tr>
<td>AUC$_{0-24}$ (µg.h/ml)</td>
<td>83.80 ± 28.80</td>
<td>60.43 ± 12.08</td>
<td>0.833</td>
</tr>
<tr>
<td>AUC$_{0-\infty}$ (µg.h/ml)</td>
<td>166.20 ± 74.50</td>
<td>104.75 ± 12.08</td>
<td>0.420</td>
</tr>
<tr>
<td>$t_{1/2}$ (h)</td>
<td>21.81 ± 3.96</td>
<td>20.71 ± 10.09</td>
<td>0.202</td>
</tr>
<tr>
<td>$K_e$ (h$^{-1}$)</td>
<td>0.0326 ± 0.0058</td>
<td>0.0381 ± 0.0124</td>
<td>0.161</td>
</tr>
</tbody>
</table>

$^a$: Abbreviations are $C_{\text{max}}$: Maximum serum concentration, $T_{\text{max}}$: Time to $C_{\text{max}}$, AUC$_{0-24}$: Area under the curve from 0 h to 24 h, AUC$_{0-\infty}$: Area under the curve from 0 h to infinity, $t_{1/2}$: Terminal half-life and $K_e$: Terminal elimination constant, $^b$: SD: Standard deviation, $^c$: Statistical significance p ≤ 0.05.
Extracts from the valerian root have been shown to inhibit CYP3A4 activity in vitro. The effects of valerian on co-administered medications in vivo appear to be less significant than those observed in vitro. Studies designed to probe in vivo drug interactions between valerian and substrates for CYP3A4 or CYP2D6 have come back negative. Minimal effects on CYP3A4 activity and no effect on CYP2D6 activity were reported following 14 days of valerian administration (1 gram/day). Similar results were found in volunteers for a variety of probe substrate relating to CYP450 3A4, 1A2, 2E1, and 2D6 following administration of valerian for a month. The results showed that valerian is unlikely to cause pharmacokinetic interaction mediated by major CYP450 enzymes.

The absorption and elimination phases of CBZ were not affected by co-administration of VAL, therefore, the bioavailability; area under the curve AUC, of CBZ was not changed significantly by VAL. Changes in bioavailability of CBZ were reported with unknown mechanisms.

The utility of animals to study drug-herb interactions is well documented. Pharmacokinetic of a drug showed not be modified by repeated blood withdrawal from the same rabbit. All five rabbits had completed the study and there were no death or replacement during the study. Clinical physical examination during and post study indicated no abnormalities. The present study showed good tolerability at the given doses for CBZ and VAL.

CONCLUSION: Despite the widespread of herbal medicines documented herb drug interactions are few. The result of the study indicated that, valerian has not altered PK parameters of CBZ in rabbits. CBZ can be used safely with VAL preparations.

ACKNOWLEDGMENT: The author would like to thank Mr. Mohammed Abuaffash, the director of Medical Relief Society-Gaza for providing the analysis facility and for Dr. Ali Abuzaid for his consultation about statistical analysis.

REFERENCES:


30. Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA and Markowitz JS: Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metabolism and Disposition 2004; 32: 1333-1336.

